IP Library Granted Patent US 10,653,661
Granted Patent B2
US 10,653,661 · App. 15/842,063 · Granted May 19, 2020

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Inventors: Neelima Khairatkar-Joshi (Thane, IN); Abhay Kulkarni (Navi Mumbai, IN); Dinesh Pradeep Wale (Maharashtra, IN); Vikram M. Bhosale (Mumbai, IN); Piyush Agarwal (Mumbai, IN); Patrick Keohane (London, GB); Sudeesh K. Tantry (Jamison, PA); Chad Oh (San Francisco, CA)
Assignee: GLENMARK SPECIALTY S.A.
A61K31/335A61K9/0043A61K31/573A61P27/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,661
App. No.
15/842,063
Granted
May 19, 2020
Kind
B2
Abstract

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

Claims (5)

1. A method of treating one or more symptoms associated with perennial allergic rhinitis in a human subject in need thereof comprising nasally administering, twice daily, to the human subject about 1330 mcg per nostril of olopatadine hydrochloride and about 50 mcg per nostril of mometasone furoate, wherein (i) the mometasone furoate and olopatadine hydrochloride are administered in a fixed-dose pharmaceutical composition, and (ii) the twice daily administration of the pharmaceutical composition provides a faster onset of action than twice daily administration of 1330 mcg per nostril of olopatadine hydrochloride alone.

2. The method of claim 1 , wherein each administration of the composition is two sprays of the composition in each nostril, and each spray comprises about 25 mcg mometasone furoate and about 665 mcg olopatadine hydrochloride.

3. The method of claim 1 , wherein the one or more symptoms are selected from nasal symptoms.

4. The method of claim 1 , wherein the one or more symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

5. The method of claim 1 , wherein the human subject is at least 12 years of age.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 26, 2023
From: GLENMARK SPECIALTY S.A.
To: GLENMARK SPECIALTY S.A.
Reel/Frame 065379/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2018
From: KHAIRATKAR-JOSHI, NEELIMA; KULKARNI, ABHAY; WALE, DINESH PRADEEP; BHOSALE, VIKRAM MANSINGH; AGARWAL, PIYUSH; KEOHANE, PATRICK; TANTRY, SUDEESH K; OH, CHAD
To: GLENMARK SPECIALTY S.A.
Reel/Frame 044845/0408 →
Priority Claims (1)
IN 3174/MUM/2013 · Oct 4, 2013 · national
Continuity (6)
Continuation In Part 15716661 · Sep 27, 2017
Continuation In Part 15691500 · Aug 30, 2017
Continuation In Part 15636120 · Jun 28, 2017
Continuation In Part 14682001 · Apr 8, 2015
Continuation In Part 14506122 · Oct 3, 2014
Related Publication 20180369187A1 · Dec 27, 2018